What Researchers Did
Researchers reviewed paper logs from January to December 2011 to evaluate the feasibility and safety of using Nitrox 50 as a breathing gas for personnel attending patients in a multiplace hyperbaric chamber.
What They Found
Out of 1,207 hyperbaric exposures for chamber personnel, Nitrox 50 was used on 978 occasions (81.0%). Median nitrogen gas-loading after the first pressurization complied with Repetitive Group Letter A, and no symptoms of decompression sickness were reported (95% CI 0.00-0.33%).
What This Means for Canadian Patients
While this study focuses on the safety of hyperbaric chamber personnel, ensuring their well-being allows for consistent and safe delivery of hyperbaric oxygen treatment to Canadian patients. The findings suggest that using Nitrox 50 could enable hyperbaric units to maintain high patient flow and treatment demands with fewer staff, potentially improving access to care.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A limitation of this study is its retrospective design, relying on paper logs which may not capture all potential health issues or detailed exposure data.